New demands of the United States under the Free Trade Agreement: pharmaceutical patents
This article is focused on the intellectual property disciplines demanded by the US to Ecuador in the process of negotiating the US-Andean Free Trade Agreement. These demands go further than Andean intellectual property norms, which are actually very favorable to the pharmaceutical corporations. Bas...
Saved in:
| 主要作者: | |
|---|---|
| 格式: | article |
| 語言: | spa |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://revistas.uasb.edu.ec/index.php/comentario/article/view/156 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
添加標簽 | 總結: | This article is focused on the intellectual property disciplines demanded by the US to Ecuador in the process of negotiating the US-Andean Free Trade Agreement. These demands go further than Andean intellectual property norms, which are actually very favorable to the pharmaceutical corporations. Basically the US requests are related to the protection of exclusivity rights applied to non-divulgated information; conditions for obligatory licenses; enhancing time protections to patents and second uses; and elimination of constraints to patentability. It is concluded that the intellectual property debate is essentially a political issue, although it appears as a technical matter. |
|---|